



IKCS: EUROPE

INTERNATIONAL KIDNEY CANCER SYMPOSIUM

22-24 APRIL 2022 • ANTWERP, BELGIUM AND VIRTUAL

SYMPOSIUM GUIDE

TABLE OF CONTENTS

Welcome Letter	2
About the Kidney Cancer Association	3
Continuing Medical Education Information	5
Program Agenda	9
Poster Listings	19
Supporters and Exhibitors	22

Join the Conversation on Social Media: We encourage all attendees to share their IKCS: Europe experience on social media. Make sure to add the hashtag **#IKCSEU22** and tag **@KidneyCancer** in all your posts!

The Kidney Cancer Association (KCA) presents the International Kidney Cancer Symposium: Europe, an opportunity for physicians, researchers, academics, and industry professionals from across the region to join and exchange ideas that will direct the future of kidney cancer research and treatment in the ultimate pursuit of a cure.

IKCS meetings are a front-row seat to emerging research, noteworthy breakthroughs, current challenges, and promising treatments in kidney cancer. The community feel promotes learning, networking, and unparalleled opportunities for mentorship and collaboration.

HEALTH AND SAFETY INFORMATION

IKCS: Europe will follow all local health and safety policies. Additional information is available on our website at kcametings.org/2022-ikcs-europe-health-and-safety.

WIFI ACCESS

NETWORK

hhonors

OR

hhonors_conference

PASSWORD

Mtg2022

WELCOME

We are pleased to welcome you to the 2022 IKCS: Europe!

After three years, we are very grateful to be together in-person once again in Antwerp, Belgium, for an exciting program that showcases the best in kidney cancer research and discovery. We also welcome all those joining virtually from around the world to exchange ideas that will direct the future of kidney cancer research.

This year, we are honored to have Dr. Tim O'Brien of Guy's and St. Thomas NHS Foundation Trust deliver the Keynote Lecture. In addition, Dr. Grant Stewart of the University of Cambridge will receive the John Fitzpatrick Award in Urology and Dr. Laurence Albiges of the Institut Gustave Roussy will receive the Pieter de Mulder Award in Oncology in recognition of their outstanding contributions to the kidney cancer field.

Make sure to spend time in the exhibit hall, network with fellow attendees both in-person and virtually (use the official Twitter hashtag #IKCSEU22), and don't forget to collect your CME credits.

We thank those who worked diligently to bring us a dynamic event while prioritizing health and safety by putting comprehensive Covid-19 protocols in place. Among those are:

- Our presenters and panelists
- Our sponsors, exhibitors, and attendees
- Our Scientific Program Planning Committee: Samra Turajlic, PhD, MRCP (Chair); Guillermo de Velasco, MD, PhD; Lars Lund, MD, DMSci; Gabriel Malouf, MD, PhD; Thomas Powles, MD, MBBS, MRCP; and Michael Staehler, MD, PhD.

We are in an exciting phase of research and discovery for kidney cancer. Your contributions to this journey and service to patients and families are an inspiration. We at the KCA are proud to support you and help forge new paths to unlocking the cure!



Sincerely,

Gretchen E. Vaughan

President and CEO, Kidney Cancer Association

#UnstoppableTogether



Look for Bristol Myers Squibb at the 2022 IKCS: Europe Meeting

Bristol Myers Squibb is a proud supporter of the 2022 IKCS: Europe Meeting and would like to thank all members for their dedication to patients.



ABOUT THE KCA

The Kidney Cancer Association was founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois, and has grown into an international non-profit organization. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.

OUR VISION is to be the universal leader in finding the cure for kidney cancer.

OUR MISSION is to be a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.

MAIL DONATIONS TO:

Please send donations to our secure lock-box:

Kidney Cancer Association

PO Box 676226, Dallas, TX 75267-6226

USA: (800) 850-9132

INTERNATIONAL: +1 847 332 1051

EMAIL: office@kidneycancer.org

“One of the Association’s most important contributions is its support of the physicians, nurses, and cancer care team members who care for patients with kidney cancer. Through our educational activities, we help ensure that the latest medical advances and best practices are shared. Our global medical conferences bring together the world’s leading technology and treatment options.”

Gretchen E. Vaughan

President and CEO, Kidney Cancer Association

PRESIDENT AND CEO

Gretchen E. Vaughan

CHIEF ADVANCEMENT OFFICER

Kendall Monroe

MEDICAL DIRECTOR

Sallie McAdoo, MS, CGC

Gretchen E. Vaughan
President & CEO
Houston, Texas

Kendall Monroe
Chief Advancement Officer
Houston, Texas

Susan Alanis
Director of Gift Operations
Houston, Texas

LaRanda Burke
Director of Finance
Houston, Texas

Radha Chitale
Director of Communications
Washington, D.C.

KCA STAFF

Rosemary Chustak
Patient Liaison
Milwaukee, Wisconsin

Christine Kelly-Weaver
Executive Assistant
Houston, Texas

Melissa Lopez
Gift Operations Associate
Houston, Texas

Sallie McAdoo
Medical Director
Houston, Texas

Emely Rodriguez
Accountant
Houston, Texas

Ashley Ruggieri
Director of Patient Advocacy and Partnerships
Philadelphia, Pennsylvania

Stephanie Shirley
Director of Advancement Services
Harrisburg, Pennsylvania

Jeanette Stensgaard
Director of Conferences and Events
Aurora, Colorado

Sarah Tuck
Program Manager
Langhorne, Pennsylvania

Jennifer Vitek
Director of Conferences and Events
Denver, Colorado

Angela Washington
Director of Operations
Houston, Texas

BOARD OF DIRECTORS

Gretchen E. Vaughan, President and CEO
Bradley C. Leibovich, MD, *Chairperson*
Noah Buntman, *Treasurer*
Jamie Graves, *Secretary*
Lisa Alderson

Ronald M. Bukowski, MD
Tessa Churchill, MD, MBA
Craig DePriester
Daniel J. George, MD
Ryan Natzke
David Perry, Esq.

Shelley Robson
Nicholas Vogelzang, MD, FACP, CASCO
(Emeritus)
Laura Wood, RN, MSN, OCN
Ruben Ybarra

MEDICAL STEERING COMMITTEE

Daniel J. George, MD, *Chairperson*
Brian Rini, MD, Vice Chair
Laurence Albiges, MD, PhD
Axel Bex, MD, PhD
Ronald M. Bukowski, MD (Emeritus)
Jose A. Karam, MD, FACS
Chung-Han Lee, MD, PhD
Bradley C. Leibovich, MD
Pavlos Msaouel, MD, PhD
Sumanta Pal, MD
W. Kimryn Rathmell, MD, PhD
Walter M. Stadler, MD, FACP (Emeritus)
Nizar M. Tannir, MD, FACP (Emeritus)
Tian Zhang, MD

CLINICAL ADVISORY BOARD

Laura S. Wood, RN, MSN, OCN (Chair)
Nancy Moldawer, RN, MSN (Co-Chair)
Nancy Ainslie, RN, BSN
Julia Batten, APRN, MSN, MPH
Nina Decker, MSW, LCSW
Patricia Fischer RN, MSN, OCN
Jan Jackson, RN
Kiran Virdee, RN, BSN, CCRN
Zita Lim, PA-C
Kathryn Nelson, RN
Virginia J. Seery, MSN, RN, ANP-BC
Meghara Walsh, RN, BSN

PATIENT & CAREGIVER ADVISORY COUNCIL

Kathleen Campbell
Steven Edwards
John Ferrell
Bruce Hill
Susan Hill
Vineeta Hiranandani
Ritchie Johnson
Benjamin Lundin
Deb Maskens
Ryan Natzke (Chair)
Marissa Willis
Salima Witt
Peggy Zuckerman

CONTINUING MEDICAL EDUCATION INFORMATION

Jointly provided by The France Foundation and The Kidney Cancer Association.



TARGET AUDIENCE

This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

STATEMENT OF NEED

Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates, researchers, and care team members to help promote learning and collaboration for advancement in the renal cancer space.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES

Upon completion of this course, the participants should be able to:

- Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma
- Identify the novel approaches to non-clear RCC patient management
- Understand the role of the tumor microenvironment in kidney cancer
- Discuss how to design biomarker driven clinical trials in kidney cancer

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

PHYSICIANS

The France Foundation designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



The 2022 IKCS: Europe - International

Kidney Cancer Symposium, Antwerp, Belgium, 22/04/2022–24/04/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME[®]) with **14** European CME credits (ECMEC[®]s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME[®] credits to an equivalent number of AMA PRA Category 1 Credits[™]. Information on the process to convert EACCME[®] credit to AMA credit can be found at ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME[®] for ECMEC[®]s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

1. Review the activity objectives and CME/CE information.
2. Participate in the CME/CE activity.
3. Go to the website: tinyurl.com/22ikcseu and log in using your email address (the same one used to register for the meeting) and your Access Key. Click the CME Information tile on the homepage, or click the CME and Evaluation link from the left-hand navigation menu. Review the instructions and click the link to complete the meeting evaluation and download a certificate.
4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

ACTIVITY STAFF DISCLOSURES

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at The Kidney Cancer Association who control content have no relevant financial relationships to disclose.

View Faculty Disclosures online by logging into the platform, tinyurl.com/22ikcseu, and clicking CME information.

DISCLOSURE OF UNLABELED USE

TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The France Foundation and the Kidney Cancer Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the Kidney Cancer Association assume no liability for the information herein.

Note: Missing disclosures were not submitted in time for printing. Their disclosures will be available during their session talks.

SOURCES OF FUNDING

Funding sources supporting this conference include the following:

- Participants' registration fees
- Exhibition booths during the event



SPONSORED SYMPOSIA*

FRIDAY 21 APRIL 2022, 12:45PM–3:45PM

Evolving Strategies for Early-Stage Renal Cell Carcinoma: The Emerging Role of Immuno-Oncology

Sponsored by Bristol Myers Squibb

Level 2, Tiffany and Shah

**All symposia are located on Level 2, Tiffany and Shah. Meals will be provided by the KCA.*

Scan to access the IKCS: Europe 2022 Conference app



FOR MOBILE:

1. Scan the QR code to access the platform on a mobile device.
2. Login with your email address and Access Key.

FOR PC:

1. Go to tinyurl.com/22ikcseu
2. Login with your email address and Access Key.

TO SUBMIT A QUESTION DURING A SESSION Q+A

1. Go to tinyurl.com/22ikcseu
2. Login with your email address and Access Key.
3. Click Program, then open the session you wish to attend.
4. To submit a question to speakers, click the Question button on the bottom right-hand corner of the window.

REGISTRATION OPEN • Level 3, Foyer
14:30–19:00

THINK TANK (BY INVITATION ONLY) • Level 2, Tiffany and Shah
15:00–19:00



Save the Dates

INTERNATIONAL KIDNEY CANCER SYMPOSIUMS



2022 IKCS: NORTH AMERICA

November 4–5, 2022

Austin, Texas | In-person & Virtual



2023 IKCS: EUROPE

21–22 April 2023

Edinburgh, Scotland | In-person & Virtual

LEARN MORE AT [KCMEETINGS.ORG](https://www.kcmeetings.org)

[kidneycancer.org](https://www.kidneycancer.org) | office@kidneycancer.org

f **@** **in** @KidneyCancerAssociation **t** @KidneyCancer

REGISTRATION OPEN • Level 3, Foyer
6:30–16:30

POSTER AND EXHIBIT HALL OPEN • Level 3, Foyer
6:30–17:15

MEET THE EXPERTS NETWORKING • Level 2, Tiffany and Shah
Meet kidney cancer experts from across Europe to discuss specific topics and make connections with colleagues.
7:00–7:50

Advocacy: Michael Staehler, MD, PhD

Career Paths Outside Academia: Lisa Pickering, MD, PhD

Oncology: Guillermo de Velasco, MD, PhD and TBD

Publications and Getting Published: Camillo Porta, MD

Research and Clinical Trial Funding: Gabriel Malouf, MD, PhD, and Samra Turajlic, PhD, MBBS, MRCP

Urology: Lars Lund, MD, PhD

BREAK • Level 3, Foyer
7:50–8:00

WELCOME AND SESSION 1: SURGICAL APPROACHES • Level 3, Belle Epoque Ballroom
8:00–9:15

WELCOME • Chair: Samra Turajlic, PhD, MBBS, MRCP, *The Francis Crick Institute/ The Royal Marsden Hospital*

CHAIR/MODERATOR • Christian Beisland, MD, PhD, *University of Bergen*

SPEAKER • Holger Moch, MD, *University Hospital Zurich*
The New WHO Classification

SPEAKER • Umberto Capitanio, MD, *San Raffaele Scientific Institute*
Risk Classification of Renal Tumors & How to Optimize Future TMN Classification

SPEAKER • Axel Bex, MD, PhD, *The Netherlands Cancer Institute*
Selecting Patients for Adjuvant Therapy

SPEAKER • Tian Zhang, MD, MHS, *UT Southwestern Medical Center*
Perioperative Indications for Systemic Therapy

Panel Question and Answer

SESSION 2: ORAL ABSTRACT SESSION • Level 3, Belle Epoque Ballroom

9:15–10:10

— **CHAIR/MODERATOR** • Michael Staehler, MD, PhD, *Ludwig-Maximilians University of Munich*

— **ORAL ABSTRACT PRESENTER** • Bernard Escudier, MD, *Institut Gustave Roussy*

Abstract 1: Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: Results from a discontinued study arm of CheckMate 9ER.

— **ORAL ABSTRACT PRESENTER** • Cristiane Decat Bergerot, PhD, *Centro de Cancer de Brasilia, Instituto Unity de Ensino e Pesquisa*

Abstract 2: Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a patient survey.

— **ORAL ABSTRACT PRESENTER** • Katharina Beyer, BSc, MSc, *Translational Oncology and Urology Research (TOUR), King's College London*

Abstract 3: A systematic review of heterogeneity in outcome reporting, definition, and measurement in localised kidney cancer.

— **ORAL ABSTRACT PRESENTER** • Will Ince, FRCR, MRCP, MRCGP, MB BS, *Addenbrooke's Hospital*

Abstract 4: 'Real world' impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC).

— Panel Question and Answer

BREAK • Level 3, Foyer

Coffee and sweet treats available in Exhibit Hall

10:10–10:25

SESSION 3: KEYNOTE • Level 3, Belle Epoque Ballroom

10:25–11:10

— **INTRODUCTION** • Samra Turajlic, PhD, MBBS, MRCP, *The Francis Crick Institute/The Royal Marsden Hospital*

— **KEYNOTE SPEAKER** • Tim O'Brien, MA, DM, FRCS (Urol), *Guy's and St. Thomas' NHS Foundation Trust*

Learning from the Extreme: Challenges in the Surgical Management of Locally Advanced and Recurrent Disease

— Question and Answer

SESSION 4: CARING FOR THE WHOLE PATIENT: NON-CLINICAL CONSIDERATIONS

Level 3, Belle Epoque Ballroom

11:10–12:15

CHAIR/MODERATOR • Daniel J. George, MD, *Duke University Medical Center*

SPEAKER • Dena Battle, *KCCure*

Misinformation and Disinformation

SPEAKER • Michael Staehler, MD, PhD, *Ludwig-Maximilians University of Munich*

Cost in RCC

SPEAKER • Désirée Louise Dräger, MD, *University of Rostock*

Psychosocial Implications of Kidney Cancer

SPEAKER • Theresa Junker, RN, PhD, *University of Southern Denmark*

Quality of Life after Renal Cell Carcinoma Treatment

SPEAKER • Rachel Giles, MD, *University Medical Center Utrecht*

The Role of Advocacy in Patient Care

Panel Question and Answer

LUNCH AND POSTER SESSION • Level 3, Foyer, Teun, Lijn

12:15–14:15

BREAK • Level 3, Teun, Lijn

12:15–12:45

NON-CME INDUSTRY SPONSORED SYMPOSIUM

Evolving Strategies for Early-Stage Renal Cell Carcinoma: The Emerging Role of Immuno-Oncology (BMS) • Level 2, Tiffany and Shah

12:45–13:45

BREAK • Level 3, Teun, Lijn

13:45–14:15

SESSION 5: SYSTEMIC THERAPY DEBATE: SELECTING FIRST-LINE THERAPY

Level 3, Belle Epoque Ballroom

14:15–15:15

- **CHAIR/MODERATOR** • Guillermo de Velasco, MD, PhD, *University Hospital 12 de Octubre*
- **DEBATE SPEAKER** • Lisa Pickering, MD, PhD, *The Royal Marsden NHS Foundation Trust*
Debate: In Favor of IO/TKI
- **DEBATE SPEAKER** • Aristotelis Bamias, MD, Medical School, *University of Athens*
Debate: In Favor of IO/IO
- **CLINICAL CASES WITH PANEL DISCUSSION** • Guillermo de Velasco
- Panel Question and Answer

SESSION 6: SYSTEMIC THERAPY DEBATE: LATER-LINE THERAPY

Level 3, Belle Epoque Ballroom

15:15–16:15

- **CHAIR/MODERATOR** • Viktor Grünwald, MD, PhD, *University-Hospital Essen*
Clinical Cases
- **DEBATE SPEAKER** • Camillo Porta, MD, IRCCS, *San Matteo University Hospital Foundation*
Debate: What We Do Know from Evidence-based 2nd Line Treatment
- **DEBATE SPEAKER** • Laurence Albiges, MD, PhD, *Institut Gustave Roussy*
Debate: What We Should Know about Clinical Considerations for 2nd Line Treatments
- Case Discussion and Panel Question and Answer

COMING TOGETHER FOR UKRAINE • Level 3, Belle Epoque Ballroom

16:15–16:30

- **SPEAKER** • Laura Bukavina, MD, MPH, *Fox Chase Cancer Center*

NETWORKING RECEPTION • Level 3, Foyer

16:30–17:30

POSTER WALKS (IN-PERSON ONLY) • Level 3, Foyer

16:30–17:15

- **POSTER WALK LEADER** • Lars Lund, MD, PhD, *University of Southern Denmark*

POSTER WALKS (ONLINE ONLY)

16:30–17:15

- **POSTER WALK LEADER** • Cristina Suárez Rodríguez, MD, *Vall d'Hebron University Hospital*

REGISTRATION OPEN • Level 3, Foyer
6:30–16:00

POSTER AND EXHIBIT HALL OPEN • Level 3, Foyer
7:30–16:00

WOMEN IN RCC NETWORKING BREAKFAST • Level 2, Tiffany and Shah
7:00–7:50

BREAK • Level 3, Teun, Lijn
7:50–8:00

SESSION 7: THE JOHN FITZPATRICK AWARD AND LECTURE

Level 3, Belle Epoque Ballroom
8:00–8:45

- **INTRODUCTION** • Axel Bex, MD, PhD, *The Netherlands Cancer Institute*
- **AWARD LECTURER** • Grant Stewart, MD, *University of Cambridge*
Strategies to Improve the Management of Initially Localized Kidney Cancer
- Question and Answer

SESSION 8: DIAGNOSTICS AND SCREENING • Level 3, Belle Epoque Ballroom
8:45–9:45

- **CHAIR/MODERATOR** • Axel Bex, MD, PhD, *The Netherlands Cancer Institute*
- **SPEAKER** • Jose Karam, MD, *University of Texas MD Anderson Cancer Center*
Diagnostics and Screening: Current Status and Future Directions
- **SPEAKER** • Gennady Bratslavsky, MD, *SUNY Upstate*
Genetics: Assessment for Hereditary Renal Cell Carcinoma
- **SPEAKER** • Eva Comperat, MD, PhD, *Hôpital Tenon, Assistance Publique-Hôpitaux de Paris*
Updates and the Future of Histopathology in Renal Cell Carcinoma
- **SPEAKER** • Orhan Oz, MD, *UT Southwestern Medical Center*
PET/CT in Renal Cancer
- **SPEAKER** • Lars Lund, MD, PhD, *University of Southern Denmark*
Management of Incidental Renal Masses: A Summary
- Panel Question and Answer

BREAK • Level 3, Foyer

Coffee and sweet treats available in Exhibit Hall

9:45–10:00

SESSION 9: BASIC SCIENCE IN RCC • Level 3, Belle Epoque Ballroom

10:00–11:00

— **CHAIR/MODERATOR** • Gabriel Malouf, MD, PhD, *Institut de Cancérologie de Strasbourg-Europe, Strasbourg University*

— **ORAL ABSTRACT PRESENTER** • Aguirre A. de Cubas, PhD, *Medical University of South Carolina*
Abstract 5: SETD2 Loss in Kidney Cancer - Setting the Stage for Synthetic Lethality

— **SPEAKER** • Ian Frew, PhD, BSc, *University Medical Center Freiburg*
Animal Models and Immunotherapy

— **SPEAKER** • Katy Beckermann, PhD, MD, *Vanderbilt University*
Targeting Metabolism in RCC: More than Just the Cancer Cells

— **SPEAKER** • Charles Drake, MD, PhD, *Columbia University Medical Center*
Macrophages and Their Role in Renal Cell Carcinoma

— Panel Question and Answer

SESSION 10: BIOMARKER BREAKDOWN • Level 3, Belle Epoque Ballroom

11:00–12:00

— **CHAIR/MODERATOR** • Bernard Escudier, MD, *Institut Gustave Roussy*

— **SPEAKER**: Samra Turajlic, PhD, MBBS, MRCP, *The Francis Crick Institute/The Royal Marsden Hospital*
Biomarker Discovery Through TCR Sequencing

— **SPEAKER** • David Braun, MD, PhD, *Yale School of Medicine*
Biomarker Discovery Through Single-cell RNA Sequencing

— **SPEAKER** • Elfriede Nöbner, PhD, *Helmholtz Zentrum München*
Vaccines and Cellular Therapies

— **SPEAKER** • John Haanen, MD, PhD, *Netherlands Cancer Institute*
What's Next? Overcoming Primary and Secondary Resistance to ICI

— Panel Question and Answer

LUNCH AND POSTER SESSION • Level 3, Foyer

12:00–14:00

SESSION 11: THE ROLE OF RADIATION THERAPY IN THE MANAGEMENT OF RENAL CELL CARCINOMA • Level 3, Belle Epoque Ballroom

14:00–14:45

- **CHAIR/MODERATOR** • Lars Lund, MD, PhD, *University of Southern Denmark*
- **SPEAKER** • Stephanie Kroeze, MD, PhD, *University Hospital Zurich*
Radiation Therapy in the Treatment of Renal Cell Carcinoma
- **SPEAKER** • Ronan Flippot, MD, MSc, *Institut Gustave Roussy*
Radiation vs. Non-radiation: Treatment of Brain Metastases
- **SPEAKER** • Marta Scorsetti, MD, *University of Milan*
Radiation in the Management of Oligometastatic Disease
- Panel Question and Answer

SESSION 12 • Level 3, Belle Epoque Ballroom

WoodFire™ (*WoodFire™ is an exciting chance to watch clinicians debate the various treatment options for each presented oncology case. It's the fiercest tumor board you'll ever see!*)

14:45–16:00

- **PANELIST** • Laurence Albiges, MD, PhD, *Institut Gustave Roussy*
Case presentation and discussion 1
- **PANELIST** • Christian Beisland, MD, PhD, *University of Bergen*
Case presentation and discussion 2
- **PANELIST** • Pedro Barata, MD, MSc, *Tulane University*
Case presentation and discussion 3
- **PANELIST** • Gennady Bratslavsky, MD, *SUNY Upstate*
Case presentation and discussion 4

REGISTRATION OPEN • Level 3, Foyer

7:00–8:30

POSTER AND EXHIBIT HALL OPEN • Level 3, Level 3 Foyer

7:00–10:00

SESSION 13: THE PIETER DE MULDER AWARD AND LECTURE: LEARNING FROM RCC

Level 3, Belle Epoque Ballroom

8:00–8:45

— **INTRODUCTION** • Thomas Powles, MBBS, MRCP, MD, *Bart's Cancer Institute*

— **AWARD LECTURER** • Laurence Albiges, MD, PhD, *Institut Gustave-Roussy*

— Question and Answer

SESSION 14: SELECTING THERAPY FOR NON-CLEAR CELL RENAL CELL CARCINOMA SUBTYPES

Level 3, Belle Epoque Ballroom

8:45–9:55

— **CHAIR/MODERATOR** • Bernard Escudier, MD, *Institut Gustave-Roussy*

— **SPEAKER**: Pedro Barata, MD, MSc, *Tulane University*

Gene expression profiling of nccRCC identifies a unique spectrum of transcriptional signatures with potential clinical relevance

— **SPEAKER** • Gabriel Malouf, MD, PhD, *Institut de Cancérologie de Strasbourg-Europe, Strasbourg University, MiT Family Translocation RCC*

— **SPEAKER** • Elizabeth P. Henske, MD, *Dana-Farber Cancer Institute*

Cysteine Depletion Induces Ferroptosis in Chromophobe RCC

— **SPEAKER** • Giuseppe Procopio, MD, *Fondazione IRCCS Istituto Nazionale Tumori*

Collecting Duct and Renal Medullary Carcinoma

— **SPEAKER** • Guillermo de Velasco, MD, PhD, *University Hospital 12 de Octubre*

Papillary Renal Cell Carcinoma

— Panel Question and Answer

SESSION 15: THERAPEUTIC MANAGEMENT: RESEARCH IN THE RCC LANDSCAPE

Level 3, Belle Epoque Ballroom

9:55–10:40

— **CHAIR/MODERATOR** • Thomas Powles, MBBS, MRCP, MD, *Bart's Cancer Institute*

— **SPEAKER** • Naveen Vasudev, MBChB, MRCP, PhD, *University of Leeds*

Withholding Therapy: Wrongful Doing or Chance for Success in Immunotherapy?

— **SPEAKER** • Janet Brown, BMedSci, MBBS, MSc, MD, FRCP, *The University of Sheffield*

Optimizing Treatment Schedules with TKI Therapy

— Panel Question and Answer

CLOSING REMARKS • Level 3, Belle Epoque Ballroom

10:40–10:50

— **SPEAKER** • Michael Staehler, MD, PhD, *Ludwig-Maximilians University of Munich*

Closing Remarks

POSTER LISTINGS

POSTER BY TOPIC

Regular Abstracts
 Case Reports
 Trials in Progress Abstracts
 Basic Science
 Imaging
 Impact of COVID-19
 Other
 Patient-Reported Outcomes
 Quality of Care and Quality Improvement
 Real-world Evidence
 Therapeutics Poster Boards
 Treatment Toxicities and Symptom Management
 Tumor Biology, Biomarkers, and Pathology


BOARD

A1- E4
 E5
 F1- F4
 A5-B1
 B2
 B3-B4
 E5
 A2, F1
 A3, B5
 A4, B6, C1-C5
 A1, D1-D4, F2-F3
 D5
 E1-E4, F4

POSTER #	TITLE	LEAD AUTHOR
A1 Abstract 1	Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: results from a discontinued study arm of CheckMate 9ER	Bernard Escudier
A2 Abstract 2	Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a patient survey 1st place Abstract Award	Cristiane Decat Bergerot
A3 Abstract 3	A systematic review of heterogeneity in outcome reporting, definition and measurement in localised kidney cancer 2nd place Abstract Award	Katharina Beyer
A4 Abstract 4	‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC) 3rd place Abstract Award	Will Ince
A5 Abstract 5	SETD2 loss in kidney cancer - Setting the stage for synthetic lethality	Aguirre A. de Cubas
B1 Abstract 7	New Evidence of Preventing Kidney Tumor Progression in Pre-clinical Mouse Model	Samy Lewiz Habib
B2 Abstract 8	PSMA-expression in renal cell carcinoma as basis for theranostic approaches – an immunohistochemical nephrectomy study	Lena M. Unterrainer

POSTER #	TITLE	LEAD AUTHOR
B3 Abstract 9	Perceptions of COVID-19 vaccination in patients with renal cell carcinoma (RCC)	Zeynep B. Zengin
B4 Abstract 10	Waning efficacy of COVID-19 vaccination at 6 months in patients with renal cell carcinoma (RCC)	Jasnoor Malhotra
B5 Abstract 11	Retention in clinical trials: the kidney cancer patient perspective	Josefine Björkqvist
B6 Abstract 12	Efficacy of frontline combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)	Lucia Carril-Ajuria
C1 Abstract 13	Complete Responses with first line (1L) antiangiogenic monotherapy in Spanish patients with metastatic renal cell carcinoma (mRCC). The ATILA study	Teresa Alonso-Gordoa
C2 Abstract 14	Real-World Clinical Outcomes of tivozanib as first-line treatment of metastatic renal cell carcinoma in Germany	Viktor Grünwald
C3 Abstract 15	Image-guided robotic radiosurgery for the treatment of metastases of renal cell carcinoma	Severin Rodler
C4 Abstract 16	Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT	Peter J. Goebell
C5 Abstract 17	Real-world clinical characteristics and treatment patterns in patients with advanced renal cell carcinoma treated with first-line immunotherapy + axitinib in Germany	Giovanni Zanotti
D1 Abstract 18	Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (aRCC): Subsequent Therapy and Survival Outcomes with Lenvatinib (L) + Everolimus (E) vs Sunitinib (S)	Thomas E. Hutson
D2 Abstract 19	From cytokine to immunotherapy: Improvements in overall survival in metastatic renal cell carcinoma in a real-life population in Austria upon 3 decades of follow-up	Dominik A. Barth
D3 Abstract 20	Profile of Dissociated response in metastatic Clear Cell Renal Cell Carcinoma and subsequent radical therapy	Mohamed Amine Tenabene

POSTER #	TITLE	LEAD AUTHOR
D4 Abstract 21	AB521 is a Novel and Potent Clinical-stage HIF-2a Inhibitor for the Treatment of Renal Cell Carcinoma	Kelsey E. Gauthier
D4 Abstract 22	Characterization and Management of Adverse Reactions in Patients with Advanced Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study)	Robert J. Motzer
E2 Abstract 24	Circulating microRNAs and treatment response to cabozantinib in metastatic clear cell renal cell carcinoma (mRCC) patients treated in the phase II CABOPRE trial.	Lucia Carril-Ajuria
E3 Abstract 25	Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)	Alexander Chehrazi-Raffle
E4 Abstract 26	Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature	Louise Geertsen
E5 Abstract 27	Renal cell carcinoma in a patient with Situs Inversus Totalis – Laparoscopic radical nephrectomy is a safe and feasible option: A case report	Benjamin Buckland
F1 Abstract 28	A Three-Arm Randomized Multicenter Phase II Trial Comparing Patient-Reported Outcome (PRO) Monitoring in Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma: ePRO vs paper-PRO, or usual care (Trial in Progress)	Takahiro Osawa
F2 Abstract 29	LITESPARK-011: Belzutifan Plus Lenvatinib Versus Cabozantinib: A Randomized, Open-Label Phase 3 Study in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti-PD-1/PD-L1 Therapy	Robert J. Motzer
F3 Abstract 30	Trial in Progress: Individualized Treatment Strategy for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma – the INDIGO phase II study	Ida Marie Lind Rasmussen
F4 Abstract 31	AURORAX-0087A: Glycosaminoglycan (GAG) scores for recurrence detection in Leibovich Points ≥ 5 clear cell renal cell carcinoma - Trial In Progress	Saeed Dabestani



KIDNEY CANCER ASSOCIATION'S
DATA FEDERATION
POWERED BY THE KCA THINK TANK

COMING SOON!

A new way to do multi-institutional research.
Visit the Kidney Cancer Association booth
to learn more.

2022 IKCS: Europe is Made Possible with the Generous Support of:

GOLD



Bristol Myers Squibb™

BRONZE





KidneyCancerAssociation®

The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding a cure for kidney cancer.

KIDNEYCANCER.ORG

office@kidneycancer.org | 800-850-9132

International: +1 847 332 1051

MAILING ADDRESS

9450 SW Gemini Drive #38269

Beaverton, OR 97008-7105

DONATION ADDRESS

PO Box 676226

Dallas, TX 75267-6226

HQ IN HOUSTON TEXAS

[@KidneyCancer](#) | [#UnstoppableTogether](#)

